An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Palynziq

Chemical Namepegvaliase-pqpz
Dosage FormInjectable (subcutaneous; 2.5 mg/0.5 mL, 10 mg/0.5 mL, 20 mg/mL)
Drug ClassEnzymes
SystemBlood
CompanyBioMarin Pharmaceutical Inc.
Approval Year2018

Indication

  • Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.
Last updated on 12/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Palynziq (pegvaliase-pqpz) Prescribing Information2018Biomarin Pharm
Document TitleYearSource
Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).2018Molecular Genetics and Metabolism
Pegvaliase for the treatment of phenylketonuria: a pivotal, double-blind randomized discontinuation phase 3 clinical trial.2018Molecular Genetics and Metabolism